This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Dermata Therapeutics’s 8K filing here.
About Dermata Therapeutics
Dermata Therapeutics, Inc, a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.
Read More
- Five stocks we like better than Dermata Therapeutics
- How to Calculate Stock Profit
- Bloom Energy: Powering the Future With Decentralized Energy
- Insider Trading – What You Need to Know
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
